We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Xencor, a biotherapeutics company developing protein and antibody therapeutics, today announced that it raised $6 million in a bridge financing from new investor Novo Nordisk and existing investors including Zen Investments.
ImmunoGen, Inc. announced today that the company has entered into an agreement that grants Biotest AG exclusive rights to use ImmunoGen's Tumor-Activated Prodrug (TAP) technology with antibodies targeting an undisclosed target to develop novel anticancer therapeutics.
Drug developer Myogen Inc. said Tuesday it extended a research collaboration with Swiss drug maker Novartis AG for work on drugs aimed at treating heart muscle disease.
Abbott and Dharmacon Inc. has announced that a collaboration to develop new therapeutic agents based on a gene silencing technology of RNA interference (RNAi).
IMPAX Laboratories, Inc. today announced that consistent with its previously stated strategic intent and timeline, it has launched IMPAX Pharmaceuticals as the company's branded products division.
The FDA is ordering PrimaPharm to stop advertisements of its drug Hydase, saying that the ads are misleading because the company fails to communicate risks associated with the product.
The FDA is opposing substantive changes to its postmarketing policies despite a recent HHS Office of Inspector General (OIG) finding that the agency does not take its postmarketing review responsibilities seriously enough.
Ocera Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of clinical candidates for the treatment of gastrointestinal and liver diseases announced today that it has raised a $12 million Series B financing.